Aldeyra said the FDA did not ask for another clinical trial for reproxalap in dry eye disease, but there is a "lack of substantial evidence" that warrants exploration about the reasons for trial failures to identify the appropriate patients for the eye drop. AbbVie holds an option to collaborate on reproxalab's commercialization.
Tenpoint Therapeutics’ Yuvezzi brings a combination approach to presbyopia compared to single mechanisms of action offered by once-daily eye drops from Orasis Pharmaceuticals, Lenz Therapeutics, and AbbVie. Yuvezzi’s commercialization will be supported by up to $235 million in financing.
Artera President Tom McIntyre talks about the practical application of AI in healthcare.
The cruel irony is that incredibly effective treatments already exist. Many people, however, cannot access them due to barriers to care
Two years after the close of the merger that formed Viatris, the company is acquiring Oyster Point Pharma and Famy Life Sciences to expand its scope in ophthalmology, one of three therapeutic areas it is now focusing on for revenue growth.
Financial terms of the deal were kept confidential. Novartis will work with Ubisoft and McGill University to accelerate development of a digital therapeutic for amblyopia, also known as lazy eye.
While well-developed in cancers, precision medicine's readiness for prime time beyond oncology varies markedly from disease to disease. But reimbursement remains a significant hurdle.
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
Shares of Philadelphia-based Spark were up more than 120 percent in premarket trading on the Nasdaq following the news.
Miki Kapoor replaces Doug Foster, who will continue as chief strategy officer of the San Francisco-based company.
One goal of FocalView is to create a more accurate way to track and measure disease progression and develop more sensitive clinical trial endpoints from the comfort of patients' homes., adding more flexibility to clinical trial design.
Opternative's complaint against eyewear retailer Warby Parker alleges that Warby violated non disclosure agreements and trade secrets to develop a rival eye exam app.
MedCity News was at the Vive conference and spoke with executives who shared their insights for the healthcare industry.
Spark Therapeutics' treatment would mark a milestone for gene therapy to treat eye diseases and could help children and adults avoid irreversible blindness.
The dry eye disease treatment space has been fairly active in the past few years from a combination of new companies and M&A deals in this area.
On the last day of the ATA conference, three panelists explored the value in telemedicine and why it's key to apply the KISS (keep it simple, stupid) principle.
If Google is able to overcome the many hurdles to bringing this device to market, it could revolutionize the eye care industry. “What’s in their patent is the Holy Grail for patients over 40 years old," said Dr. Jeffrey Sonsino, an optometrist in Nashville, Tennessee.
The yet-unnamed app, for iPhone and iPad, is intended to provide decision support — via the IBM Cloud — and assist in the selection of implantable intraocular lenses.